Recent Finacing
Recent Raise
Carver Biosciences is a Boston gene therapy company developing a programmable CRISPR/Cas13 antiviral platform using guide RNAs to cleave viral RNA, conducting cell and disease-model proof‑of‑concept studies with CROs.
Focus Areas
Recent Investors
Funding round
Investor
See the team members at Carver Biosciences.
